Bristol Myers Squibb’s preliminary outlook for the quarter ended December 2025 projects revenue growth of approximately 3% year-over-year, driven principally by continued momentum in Opdivo sales, which are expected to rise by mid-teens percentage points. Wall Street consensus anticipates adjusted EPS of roughly 1.70, a modest sequential uptick from the prior quarter’s 1.63 figure. Management flagged sustained generic competition for legacy immunology assets, forecasting a low-single-digit decline in those franchises. R&D investment is slated to increase by around 5% versus the prior year, reflecting heavier late-stage trial commitments in oncology and cardiovascular indications. This mix should maintain operating margin near 32%, in line with the company’s full-year target.

According to the latest 13F filings, Capital Management Corp VA expanded its stake by 9.6%, adding 9,815 shares to reach a total position of 111,670 shares valued at just over 5.0 million. Charles Schwab Investment Management lifted its holdings by nearly 17%, incrementally acquiring more than 10 million shares since the second quarter, while Arrowstreet Capital boosted its allocation by 428%, and Norges Bank entered a new position valued north of 1.5 billion. Overall institutional ownership stands at approximately 76%, underscoring broad confidence among large sovereign and corporate funds in BMS’s mid-term pipeline execution.

Analyst coverage remains mixed but tilted toward cautious optimism: seven firms maintain a Buy rating, twelve issue Hold, and one assigns a Sell, yielding a consensus recommendation of Hold. Target prices range from the low-50s to the mid-60s, reflecting varied assumptions around franchise transitions. In early January, the board approved a quarterly dividend increase of 1.6%, raising the payout to 0.63 per share, which translates to an annualized yield of roughly 4.6%. The company’s dividend payout ratio now stands near 85%, consistent with its commitment to return capital while preserving flexibility for pipeline investments.